CoChat
Sign Up
Cited by 1,116

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Selective neuronal vulnerability in Parkinson disease

Surmeier, D. James, Obeso, José A., Halliday, Glenda M.·2017·Nature Reviews Neuroscience
DOI 10.1038/nrn.2016.178PMC PMC5564322
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrn.2016.178

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Oligomeric α-Syn species appear prone to uptake and spread from cell-to-cell in a prion-like manner, leading to templated misfolding of native α-Syn and formation of aggregates throughout the brain.

    “Particularly, the oligomeric α-Syn species appear to be prone to uptake and spread from cell-to-cell in a prion-like manner, leading to the templated misfolding of the native forms of α-Syn and formation of α-Syn aggregates throughout the brain, which are the defining pathological features of Parkinson’s disease (PD) and dementia with Lewy body (DLB) [12–19].”

    From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [14]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 155

  1. Berg, D. et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson's disease. Mov. Disord. 29, 454–462 (2014). This article reviews clinical and biological knowledge on PD showing that LP is not essential for cPD and occurs in a large proportion of patients who may not have cPD. · DOI
  2. Hornykiewicz, O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov. Disord. 17, 501–508 (2002). · DOI
  3. Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13–24 (2012). · DOI · Paper page
  4. Dijkstra, A. A. et al. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Mov. Disord. 29, 1244–1251 (2014). This paper describes a negative correlation between neuronal density and local α-syn burden in the SN of patients with PD and shows that the severity of neurodegeneration and local burden of α-syn pathological conditions are closely coupled during disease progression. · DOI
  5. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121–134 (2004). This seminal paper reviews the evidence supporting the notion that LP is distributed and staged in PD. · DOI · Paper page
  6. Beach, T. G. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613–634 (2009). · DOI · Paper page
  7. Del Tredici, K., Rüb, U., de Vos, R. A., Bohl, J. R. & Braak, H. Where does parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61, 413–426 (2002). · DOI · Paper page
  8. Kosaka, K., Yoshimura, M., Ikeda, K. & Budka, H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree — a new disease? Clin. Neuropathol. 3, 185–192 (1984).
  9. Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M. & Pearce, R. K. B. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α-synuclein staging. Neuropathol. Appl. Neurobiol. 34, 284–295 (2008). · DOI
  10. Halliday, G., McCann, H. & Shepherd, C. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Expert Rev. Neurother. 12, 673–686 (2012). This review evaluates the main elements underpinning the Braak hypothesis of propagation, comparing data for both PD and the similar pathological entity of dementia with Lewy bodies, as well as data using cohorts with potential prodromal features of PD. · DOI
  11. Doherty, K. M. et al. Parkin disease: a clinicopathologic entity? JAMA Neurol. 70, 571–579 (2013). · DOI
  12. Kingsbury, A. E. et al. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov. Disord. 25, 2508–2515 (2010). · DOI
  13. Dugger, B. N. & Dickson, D. W. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol. 120, 633–639 (2010). · DOI
  14. Braak, H. & Del Tredici, K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv. Anat. Embryol. Cell Biol. 201, 1–119 (2009).
  15. Mendez, I. et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14, 507–509 (2008). · DOI
  16. Kalia, L. V. & Kalia, S. K. α-Synuclein and Lewy pathology in Parkinson's disease. Curr. Opin. Neurol. 28, 375–381 (2015). · DOI
  17. Kirik, D. et al. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780–2791 (2002). · DOI · Paper page
  18. Kirik, D. et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 2884–2889 (2003). · DOI
  19. Maingay, M., Romero-Ramos, M., Carta, M. & Kirik, D. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol. Dis. 23, 522–532 (2006). · DOI
  20. Ulusoy, A. et al. Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol. Med. 5, 1051–1059 (2013). · DOI
  21. Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953 (2012). This was the first demonstration that pre-formed α-syn fibrils can propagate from one neuron to another and induce cell death in vivo when inoculated into the brain of mice. · DOI · Paper page
  22. Masuda-Suzukake, M. et al. Prion-like spreading of pathological α-synuclein in brain. Brain 136, 1128–1138 (2013). · DOI · Paper page
  23. Rey, N. L. et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J. Exp. Med. 213, 1759–1778 (2016). This paper provides the first clear evidence of transneuronal propagation of pre-formed α-syn fibril-induced pathology from the olfactory bulb in mice. · DOI
  24. Recasens, A. et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351–362 (2014). This paper used purified pathological α-syn from the SN of patients with PD to show the intracellular and presynaptic accumulation of endogenous α-syn and the progressive axon-initiated neurodegeneration. · DOI
  25. Mao, X. et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016). · DOI · Paper page
  26. Shrivastava, A. N. et al. α-Synuclein assemblies sequester neuronal α3-Na+/K+-ATPase and impair Na+ gradient. EMBO J. 34, 2408–2423 (2015). · DOI
  27. Walsh, D. M. & Selkoe, D. J. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 17, 251–260 (2016). · DOI
  28. Sacino, A. N. et al. Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. J. Neurochem. http://dx.doi.org/10.1111/jnc.13743 (2016). · DOI
  29. Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M.-Y. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135–2146 (2014). · DOI · Paper page
  30. Volpicelli-Daley, L. A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71 (2011). · DOI · Paper page
  31. Helwig, M. et al. Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice. Brain 139, 856–870 (2016). Using viral gene delivery of an α-syn expression construct to the vagus nerve, the authors examined the propagation of different forms of α-syn through the brainstem; they found that endogenous α-syn impeded, rather than promoted, the spread of oligomeric forms of α-syn. · DOI
  32. Olanow, C. W. & Brundin, P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov. Disord. 28, 31–40 (2013). · DOI
  33. Wall, N. R., Wickersham, I. R., Cetin, A., De La Parra, M. & Callaway, E. M. Monosynaptic circuit tracing in vivo through Cre-dependent targeting and complementation of modified rabies virus. Proc. Natl Acad. Sci. USA 107, 21848–21853 (2010). · DOI
  34. Koch, C. & Reid, R. C. Neuroscience: observatories of the mind. Nature 483, 397–398 (2012). · DOI
  35. Watabe-Uchida, M., Zhu, L., Ogawa, S. K., Vamanrao, A. & Uchida, N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74, 858–873 (2012). · DOI
  36. Halliday, G. M., Song, Y. J. C. & Harding, A. J. Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease. J. Neural Transm. 118, 713–719 (2011). · DOI
  37. Damier, P., Hirsch, E. C., Agid, Y. & Graybiel, A. M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122, 1437–1448 (1999). · DOI
  38. Halliday, G. M. et al. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J. Clin. Neurosci. 3, 52–60 (1996). · DOI
  39. Halliday, G. M. et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27, 373–385 (1990). · DOI
  40. Harding, A. J., Stimson, E., Henderson, J. M. & Halliday, G. M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125, 2431–2445 (2002). · DOI
  41. Henderson, J. M., Carpenter, K., Cartwright, H. & Halliday, G. M. Degeneration of the centré median–parafascicular complex in Parkinson's disease. Ann. Neurol. 47, 345–352 (2000). · DOI
  42. Thannickal, T. C. et al. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130, 1586–1595 (2007). · DOI · Paper page
  43. Fronczek, R. et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. Brain 131, e88 (2008). · DOI
  44. Kremer, H. P. H. & Bots, G. T. A. M. Lewy bodies in the lateral hypothalamus: do they imply neuronal loss? Mov. Disord. 8, 315–320 (1993). · DOI
  45. Jellinger, K. A. Formation and development of Lewy pathology: a critical update. J. Neurol. 256, 270–279 (2009). · DOI
  46. Ansorge, O., Daniel, S. E. & Pearce, R. K. Neuronal loss and plasticity in the supraoptic nucleus in Parkinson's disease. Neurology 49, 610–613 (1997). · DOI
  47. MacDonald, V. & Halliday, G. M. Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov. Disord. 17, 1166–1173 (2002). · DOI
  48. Pedersen, K. M., Marner, L., Pakkenberg, H. & Pakkenberg, B. No global loss of neocortical neurons in Parkinson's disease: a quantitative stereological study. Mov. Disord. 20, 164–171 (2005). · DOI
  49. Sara, S. J. & Bouret, S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neuron 76, 130–141 (2012). · DOI · Paper page
  50. Pfaff, D. W., Martin, E. M. & Faber, D. Origins of arousal: roles for medullary reticular neurons. Trends Neurosci. 35, 468–476 (2012). · DOI
  51. Aston-Jones, G. & Waterhouse, B. Locus coeruleus: from global projection system to adaptive regulation of behavior. Brain Res. 1645, 75–78 (2016). · DOI
  52. Alexandre, C., Andermann, M. L. & Scammell, T. E. Control of arousal by the orexin neurons. Curr. Opin. Neurobiol. 23, 752–759 (2013). · DOI
  53. Palmiter, R. D. Dopamine signaling as a neural correlate of consciousness. Neuroscience 198, 213–220 (2011). · DOI
  54. Saper, C. B. The central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Annu. Rev. Neurosci. 25, 433–469 (2003). · DOI · Paper page
  55. Silvani, A., Calandra-Buonaura, G., Dampney, R. A. L. & Cortelli, P. Brain–heart interactions: physiology and clinical implications. Philos. Trans. A Math. Phys. Eng. Sci. 374, 20150181 (2016). · DOI
  56. Miskovic, V. & Schmidt, L. A. Social fearfulness in the human brain. Neurosci. Biobehav. Rev. 36, 459–478 (2012). · DOI · Paper page
  57. Matsuda, W. et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 29, 444–453 (2009). · DOI · Paper page
  58. Martinez-Gonzalez, C., Bolam, J. P. & Mena-Segovia, J. Topographical organization of the pedunculopontine nucleus. Front. Neuroanat. 5, 22 (2011). · DOI
  59. Hornung, J.-P. The human raphe nuclei and the serotonergic system. J. Chem. Neuroanat. 26, 331–343 (2003). · DOI · Paper page
  60. Ratcliffe, E. M., Farrar, N. R. & Fox, E. A. Development of the vagal innervation of the gut: steering the wandering nerve. Neurogastroenterol. Motil. 23, 898–911 (2011). · DOI
  61. Baufreton, J. et al. Sparse but selective and potent synaptic transmission from the globus pallidus to the subthalamic nucleus. J. Neurophysiol. 102, 532–545 (2009). · DOI
  62. Hu, B., Yang, N., Qiao, Q.-C., Hu, Z.-A. & Zhang, J. Roles of the orexin system in central motor control. Neurosci. Biobehav. Rev. 49, 43–54 (2015). · DOI
  63. Liu, A. K. L., Chang, R. C.-C., Pearce, R. K. B. & Gentleman, S. M. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol. 129, 527–540 (2015). · DOI
  64. Bolam, J. P. & Pissadaki, E. K. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov. Disord. 27, 1478–1483 (2012). · DOI
  65. Hunn, B. H. M., Cragg, S. J., Bolam, J. P., Spillantini, M. G. & Wade-Martins, R. Impaired intracellular trafficking defines early Parkinson's disease. Trends Neurosci. 38, 178–188 (2015). This review highlights the potential role of intracellular trafficking in PD pathogenesis, which is particularly important in view of the growing importance of RAB proteins. · DOI
  66. Pacelli, C. et al. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr. Biol. 25, 2349–2360 (2015). · DOI
  67. Zhou, F.-M., Wilson, C. J. & Dani, J. A. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J. Neurobiol. 53, 590–605 (2002). · DOI
  68. Surmeier, D. J., Guzman, J. N., Sanchez, J. & Schumacker, P. T. Physiological phenotype and vulnerability in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2, a009290 (2012). · DOI
  69. Nedergaard, S., Flatman, J. A. & Engberg, I. Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol. 466, 727–747 (1993). · DOI
  70. Puopolo, M., Raviola, E. & Bean, B. P. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci. 27, 645–656 (2007). · DOI
  71. Guzman, J. N., Sánchez-Padilla, J., Chan, C. S. & Surmeier, D. J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29, 11011–11019 (2009). · DOI
  72. Mercuri, N. B. et al. Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br. J. Pharmacol. 113, 831–838 (1994). · DOI
  73. Chan, C. S. et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447, 1081–1086 (2007). · DOI
  74. Foehring, R. C., Zhang, X. F., Lee, J. C. F. & Callaway, J. C. Endogenous calcium buffering capacity of substantia nigral dopamine neurons. J. Neurophysiol. 102, 2326–2333 (2009). · DOI
  75. Khaliq, Z. M. & Bean, B. P. Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J. Neurosci. 30, 7401–7413 (2010). · DOI · Paper page
  76. Philippart, F. et al. Differential somatic Ca2+ channel profile in midbrain dopaminergic neurons. J. Neurosci. 36, 7234–7245 (2016). · DOI
  77. Sánchez-Padilla, J. et al. Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat. Neurosci. 17, 832–840 (2014). · DOI
  78. Kang, Y. & Kitai, S. T. Electrophysiological properties of pedunculopontine neurons and their postsynaptic responses following stimulation of substantia nigra reticulata. Brain Res. 535, 79–95 (1990). · DOI
  79. Putzier, I., Kullmann, P. H. M., Horn, J. P. & Levitan, E. S. CaV1.3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J. Neurosci. 29, 15414–15419 (2009). · DOI
  80. Guzman, J. N. et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696–700 (2010). This is the first demonstration that Ca2+ entry through Cav1 channels during pacemaking elevates mitochondrial oxidant stress in SN DA neurons; the authors examined ex vivo brain slices from young adult mice and also showed that this oxidant stress was exacerbated by deletion of the gene encoding protein deglycase DJ1. · DOI
  81. Hayashi, T., Rizzuto, R., Hajnóczky, G. & Su, T.-P. MAM: more than just a housekeeper. Trends Cell Biol. 19, 81–88 (2009). · DOI · Paper page
  82. Balaban, R. S. The role of Ca2+ signaling in the coordination of mitochondrial ATP production with cardiac work. Biochim. Biophys. Acta 1787, 1334–1341 (2009). · DOI
  83. Nicholls, D. G. Mitochondria in the life and death of neurons. Essays Biochem. 33, 43–52 (1998). · DOI
  84. Dragicevic, E., Schiemann, J. & Liss, B. Dopamine midbrain neurons in health and Parkinson's disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience 284, 798–814 (2015). · DOI
  85. Albin, R. L., Young, A. B. & Penney, J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366–375 (1989). · DOI · Paper page
  86. Gerfen, C. R. & Surmeier, D. J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 34, 441–466 (2011). · DOI
  87. Votyakova, T. V. & Reynolds, I. J. Δψm-dependent and -independent production of reactive oxygen species by rat brain mitochondria. J. Neurochem. 79, 266–277 (2001). · DOI · Paper page
  88. Brimblecombe, K. R., Gracie, C. J., Platt, N. J. & Cragg, S. J. Gating of dopamine transmission by calcium and axonal N-, Q-, T- and L-type voltage-gated calcium channels differs between striatal domains. J. Physiol. 593, 929–946 (2015). · DOI
  89. de Vries, R. L. A. & Przedborski, S. Mitophagy and Parkinson's disease: be eaten to stay healthy. Mol. Cell. Neurosci. 55, 37–43 (2013). · DOI
  90. Wong, E. & Cuervo, A. M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13, 805–811 (2010). · DOI · Paper page
  91. Gupta, A., Dawson, V. L. & Dawson, T. M. What causes cell death in Parkinson's disease? Ann. Neurol. 64, S3–S15 (2009). · DOI
  92. Nagley, P., Higgins, G. C., Atkin, J. D. & Beart, P. M. Multifaceted deaths orchestrated by mitochondria in neurones. Biochim. Biophys. Acta 1802, 167–185 (2010). · DOI
  93. Rcom-H'cheo-Gauthier, A., Goodwin, J. & Pountney, D. L. Interactions between calcium and alpha-synuclein in neurodegeneration. Biomolecules 4, 795–811 (2014). · DOI
  94. Nath, S., Goodwin, J., Engelborghs, Y. & Pountney, D. L. Raised calcium promotes α-synuclein aggregate formation. Mol. Cell. Neurosci. 46, 516–526 (2011). · DOI
  95. Dufty, B. M. et al. Calpain-cleavage of α-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725–1738 (2007). · DOI
  96. Diepenbroek, M. et al. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice. Hum. Mol. Genet. 23, 3975–3989 (2014). · DOI
  97. Melachroinou, K. et al. Deregulation of calcium homeostasis mediates secreted α-synuclein-induced neurotoxicity. Neurobiol. Aging 34, 2853–2865 (2013). · DOI
  98. Caraveo, G. et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. Proc. Natl Acad. Sci. USA 111, E3544–E3552 (2014). · DOI
  99. Reeve, A., Simcox, E. & Turnbull, D. Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res. Rev. 14, 19–30 (2014). This article summarizes and discusses how ageing might make SN neurons especially vulnerable to changes in protein metabolism and mitochondrial function. · DOI
  100. Duda, J., Pötschke, C. & Liss, B. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. J. Neurochem. 139, 156–178 (2016). · DOI
  101. Beilina, A. & Cookson, M. R. Genes associated with Parkinson's disease: regulation of autophagy and beyond. J. Neurochem. 139 (Suppl. 1), 91–107 (2015). The authors review the proposition that many known PD-related genes can be assigned to pathways that affect autophagy and mitochondrial quality control through mitophagy.
  102. Cookson, M. R. α-Synuclein and neuronal cell death. Mol. Neurodegener. 4, 9 (2009). · DOI
  103. Gegg, M. E. & Schapira, A. H. V. Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol. Dis. 90, 43–50 (2016). · DOI
  104. Schneider, J. L. & Cuervo, A. M. Autophagy and human disease: emerging themes. Curr. Opin. Genet. Dev. 26, 16–23 (2014). · DOI
  105. Jellinger, K. A. & Jellinger, K. A. A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta 1792, 730–740 (2009). This review summarizes the deviation from the Braak staging model and the difficulty oflinking LP and disease symptom severity. · DOI
  106. Pissadaki, E. K. & Bolam, J. P. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front. Comput. Neurosci. 7, 13 (2013). · DOI
  107. Liss, B. & Roeper, J. Individual dopamine midbrain neurons: functional diversity and flexibility in health and disease. Brain Res. Rev. 58, 314–321 (2008). · DOI
  108. German, D. C., Manaye, K. F., Sonsalla, P. K. & Brooks, B. A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. NY Acad. Sci. 648, 42–62 (1992). · DOI
  109. Dopeso-Reyes, I. G. et al. Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques. Front. Neuroanat. 8, 146 (2014). · DOI
  110. McCormack, A. L., Atienza, J. G., Langston, J. W. & Di Monte, D. A. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience 141, 929–937 (2006). · DOI
  111. Bender, A. et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J. Neurol. 255, 1231–1235 (2008). · DOI
  112. Roberts, H. L. & Brown, D. R. Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules 5, 282–305 (2015). This review nicely summarizes the literature linking α-syn and neuronal toxicity. · DOI
  113. Halliday, G., Hely, M., Reid, W. & Morris, J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 115, 409–415 (2008). · DOI
  114. Petit, G. H., Olsson, T. T. & Brundin, P. The future of cell therapies and brain repair: Parkinson's disease leads the way. Neuropathol. Appl. Neurobiol. 40, 60–70 (2014). · DOI
  115. Brundin, P. & Kordower, J. H. in Functional Neural Transplantation III — Primary and Stem Cell Therapies for Brain Repair, Part I (eds Dunnett, S. B. & Bjorklund, A.) 221–241 (Elsevier, 2012). · DOI
  116. Li, J.-Y. et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 25, 1091–1096 (2010). · DOI
  117. Brini, M., Calì, T., Ottolini, D. & Carafoli, E. Neuronal calcium signaling: function and dysfunction. Cell. Mol. Life Sci. 71, 2787–2814 (2014). · DOI
  118. Guardia-Laguarta, C., Area-Gomez, E., Schon, E. A. & Przedborski, S. A new role for α-synuclein in Parkinson's disease: alteration of ER-mitochondrial communication. Mov. Disord. 30, 1026–1033 (2015). This review advances thenovel concept that α-syn affects neuronal function by modulating endoplasmic reticulum–mitochondrial crosstalk. · DOI
  119. McCoy, M. K. & Cookson, M. R. Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid. Redox Signal. 16, 869–882 (2012). · DOI
  120. Dryanovski, D. I. et al. Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 33, 10154–10164 (2013). · DOI
  121. Mosharov, E. V. et al. Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 62, 218–229 (2009). · DOI
  122. Subramaniam, M. et al. Mutant α-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels. J. Neurosci. 34, 13586–13599 (2014). · DOI
  123. Brichta, L. et al. Identification of neurodegenerative factors using translatome-regulatory network analysis. Nat. Neurosci. 18, 1325–1333 (2015). · DOI · Paper page
  124. Murchison, D. & Griffith, W. H. Calcium buffering systems and calcium signaling in aged rat basal forebrain neurons. Aging Cell 6, 297–305 (2007). · DOI
  125. Hafkemeijer, A., van der Grond, J. & Rombouts, S. A. R. B. Imaging the default mode network in aging and dementia. Biochim. Biophys. Acta 1822, 431–441 (2012). · DOI
  126. Hammond, C., Bergman, H. & Brown, P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci. 30, 357–364 (2007). · DOI
  127. Thibault, O., Gant, J. C. & Landfield, P. W. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 6, 307–317 (2007). · DOI
  128. Hurley, M. J., Gentleman, S. M. & Dexter, D. T. Calcium CaV1 channel subtype mRNA expression in Parkinson's disease examined by in situ hybridization. J. Mol. Neurosci. 55, 1–10 (2014).
  129. Hurley, M. J., Brandon, B., Gentleman, S. M. & Dexter, D. T. Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136, 2077–2097 (2013). · DOI
  130. Ilijic, E., Guzman, J. N. & Surmeier, D. J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 43, 364–371 (2011). · DOI
  131. Kupsch, A. et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 741, 185–196 (1996). · DOI
  132. Singh, A., Verma, P., Balaji, G., Samantaray, S. & Mohanakumar, K. P. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neurochem. Int. 99, 221–232 (2016). · DOI
  133. Lee, Y.-C. et al. Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study. PLoS ONE 9, e98961 (2014). · DOI
  134. Pasternak, B. et al. Use of calcium channel blockers and Parkinson's disease. Am. J. Epidemiol. 175, 627–635 (2012). · DOI
  135. Marras, C. et al. Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann. Neurol. 71, 362–369 (2012). · DOI
  136. Ritz, B. et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600–606 (2010). · DOI
  137. Becker, C., Jick, S. S. & Meier, C. R. Use of antihypertensives and the risk of Parkinson disease. Neurology 70, 1438–1444 (2008). · DOI
  138. Gudala, K., Kanukula, R. & Bansal, D. Reduced risk of Parkinson's disease in users of calcium channel blockers: a meta-analysis. Int. J. Chron. Dis. 2015, 697404 (2015).
  139. Mullin, S. & Schapira, A. The genetics of Parkinson's disease. Br. Med. Bull. 114, 39–52 (2015). This article reviews the role of genome-wide association studies in deciphering inter-related genetic mechanisms and biochemical pathways. · DOI
  140. Lin, M. K. & Farrer, M. J. Genetics and genomics of Parkinson's disease. Genome Med. 6, 48 (2014). · DOI
  141. Poulopoulos, M., Levy, O. A. & Alcalay, R. N. The neuropathology of genetic Parkinson's disease. Mov. Disord. 27, 831–842 (2012). · DOI
  142. Konno, T., Ross, O. A., Puschmann, A., Dickson, D. W. & Wszolek, Z. K. Autosomal dominant Parkinson's disease caused by SNCA duplications. Parkinsonism Relat. Disord. 22 (Suppl. 1), 1–6 (2016). · DOI
  143. Cuervo, A. M. & Wong, E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 24, 92–104 (2014). · DOI
  144. Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S. & Selkoe, D. J. Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 289, 21490–21507 (2014). · DOI
  145. Calì, T., Ottolini, D., Negro, A. & Brini, M. α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 287, 17914–17929 (2012). · DOI
  146. Guardia-Laguarta, C., Area-Gomez, E., Schon, E. A. & Przedborski, S. Novel subcellular localization for α-synuclein: possible functional consequences. Front. Neuroanat. 9, 17 (2015). · DOI · Paper page
  147. Cookson, M. R. LRRK2 pathways leading to neurodegeneration. Curr. Neurol. Neurosci. Rep. 15, 564–510 (2015). · DOI
  148. Esteves, A. R., Swerdlow, R. H. & Cardoso, S. M. LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp. Neurol. 261, 206–216 (2014). · DOI
  149. Martin, I., Kim, J. W., Dawson, V. L. & Dawson, T. M. LRRK2 pathobiology in Parkinson's disease. J. Neurochem. 131, 554–565 (2014). · DOI
  150. Kalia, L. V. et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 72, 100–105 (2015). · DOI
  151. Bonifati, V. Autosomal recessive parkinsonism. Parkinsonism Relat. Disord. 18 (Suppl. 1), S4–S6 (2012). · DOI
  152. Kirkwood, T. B. L. Global aging and the brain. Nutr. Rev. 68 (Suppl. 2), 65–69 (2010). · DOI
  153. Sahin, E. & DePinho, R. A. Axis of ageing: telomeres, p53 and mitochondria. Nat. Rev. Mol. Cell Biol. 13, 397–404 (2012). · DOI · Paper page
  154. Collier, T. J., Kanaan, N. M. & Kordower, J. H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 12, 359–366 (2011). · DOI
  155. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003). · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Surmeier, D. J., Obeso, J. A., & Halliday, G. M.
Venue
Nature Reviews Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2017-01-20
Volume
18
Issue
2
Pages
101-113
ISSN
  • 1471-003X
  • 1471-0048
DOI
10.1038/nrn.2016.178
PMC
PMC5564322
Cited by
1,116
References
36
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review